BioTuesdays
FSD Pharma & Lucid Psycheceuticals logo

FSD Pharma acquires Lucid Psycheceuticals

FSD Pharma (NASDAQ, CSE:HUGE; FRA:0K9) completed the acquisition of Lucid Psycheceuticals, a Toronto-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat mental health...

111 inc logo

111, Inc. in $10-million share repurchase program

The board of Shanghai-based 111, Inc. (NASDAQ:YI) authorized a share repurchase program of up to $10-million of the company’s Class A ordinary shares in the form of American depositary shares in the next 12 months. The...

111 inc logo

111 Inc. Q2 net revenue jumps 86.5%

Shanghai-based 111 Inc. reported net revenue rose 86.5% for the second quarter to $468.4-million (RMB3.0-billion). Mr. Junling Liu, co-founder, chairman, and CEO of 111, said the second quarter represented another...

Lucid Psycheceuticals Logo

FSD Pharma to acquire Lucid Psycheceuticals

FSD Pharma (NASDAQ:HUGE; CSE:HUGE; FRA:0K9A) agreed to acquire all the shares of closely-held, Lucid Psycheceuticals, for approximately $9-million in FSD Pharma stock.  “Lucid has successfully developed a strong...

111 inc logo

111, Inc. deepens partnership with Bayer

111, Inc. (NASDAQ:YI) has expanded its existing partnership with Bayer Healthcare in China. The original partnership was signed in September 2020 and involved collaborating on drug commercialization initiatives in China...